CClinicalTrials.gg
CompletedNCT05000619Updated Dec 1, 2022

Encouraging Overdue Healthcare Appointment Scheduling Among Patients With Chronic Diseases

An interventional study of Outreach mailer and Humor/Salience in Health Promotion, Prevention and Risk Reduction Behavior, sponsored by Geisinger Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Geisinger Clinic · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
21,562
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to determine the most effective messages for encouraging patients with chronic conditions, who have not seen their doctor in at least one year, to return to the clinic. Study participants will receive postcards or letters encouraging them to make an appointment. Researchers will assess whether messages increase appointment scheduling (and attendance).

Read the detailed description

About 18,500 Geisinger patients, Geisinger Health Plan members, and Medicaid patients with chronic illness have not been seen in a clinic for at least one year, which is concerning because regular appointments are necessary for chronic disease management. Geisinger is therefore working to encourage those with chronic illness and overdue appointments to return to the clinic.

In the present study, patients will either receive a mailer (with a message encouraging them to schedule an appointment with their physician), or no mailer. The purpose of the study is to compare three different mailers to assess which is most effective at encouraging patients to schedule and attend an appointment. The three mailers include (1) a standard outreach postcard (emphasizing that we are "checking in" with the patient), and, informed by behavioral science research, (2) a postcard with a cartoon and humorous messages and (3) a letter signed by a physician. The study will compare the effectiveness of the three experimental mailer arms to each other and to a no-contact control arm.

02

Conditions studied

  • Health Promotion
  • Prevention
  • Risk Reduction Behavior

Browse trials for

03

In context

Chronic Disease

990 studies on the registry are indexed under Chronic Disease; 178 are open to participants now.

This study's enrollment of 21,562 is above the median of 120 across 722 interventional studies indexed under Chronic Disease.

Browse Chronic Disease studies →

Lead sponsor

Geisinger Clinic is the lead sponsor of 125 studies on the registry; 21 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Geisinger patient, Geisinger Health Plan member or Medicaid patient
  • Chronic illness
  • No appointment for > 1 year
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
21,562 participants (actual)

Study arms

  • Experimental
    Outreach Postcard

    This group receives a postcard with a stock image on the front and a message encouraging regular visits to manage health on the back.

    Behavioral: Outreach mailer

  • Experimental
    Humorous Postcard

    This group receives a postcard with with a cartoon image and a visit-related joke on the front and a humorous message on the back, with additional information about why visits are important, and what to expect at the appointment.

    Behavioral: Outreach mailer · Behavioral: Humor/Salience · Behavioral: Information

  • Experimental
    Physician Letter

    This group receives a personalized letter signed by a physician with information about why visits are important, and what to expect at the appointment.

    Behavioral: Outreach mailer · Behavioral: Doctor's authority · Behavioral: Information

  • No intervention
    No-contact Control

    This group will not receive a study mailer during the trial.

Interventions

  • BehavioralOutreach mailer

    Postcard or letter

  • BehavioralHumor/Salience

    Funny cartoon

  • BehavioralDoctor's authority

    Letter from a doctor

  • BehavioralInformation

    Information about benefits of the appointment

06

What researchers measure

Primary outcomes

  1. Patients - Appointment scheduling

    Proportion of Geisinger patients who schedule an appointment

    Time frame: 30 days

Secondary outcomes

  1. Patients - Appointment scheduling - Comparing mailers

    Proportion of Geisinger patients who schedule an appointment, comparing relative efficacy of the mailers

    Time frame: 30 days

  2. Patients - Attendance at scheduled appointments within 180 days of mailer

    Proportion of appointments (from the primary outcome) that were attended. This outcome focuses on attendance at appointments that were scheduled within 30 days of the mailer drop date. It is possible to schedule an appointment months in advance, so the Time Frame needs to be long to capture attendance at any appointment scheduled within 30 days of the mailer. 180 days should be sufficient to capture all scheduled appointments.

    Time frame: 180 days

  3. Patients, Members & Medicaid - Attendance at any appointment

    Attendance at any appointment within 30 days of drop date

    Time frame: 30 days

  4. Patients, Members & Medicaid - Attendance at any appointment

    Attendance at any appointment within 90 days of drop date

    Time frame: 90 days

  5. Patients, Members & Medicaid - Attendance at any appointment

    Attendance at any appointment within 180 days of drop date

    Time frame: 180 days

  6. Patients, Members & Medicaid - Timing of appointment

    Number of days between the drop date and any appointment captured in Secondary Outcome 3

    Time frame: 30 days

  7. Patients, Members & Medicaid - Timing of appointment

    Number of days between the drop date and any appointment captured in Secondary Outcome 4

    Time frame: 90 days

  8. Patients, Members & Medicaid - Timing of appointment

    Number of days between the drop date and any appointment captured in Secondary Outcome 5

    Time frame: 180 days

Other outcomes

  1. Patients - Appointment scheduling - Comparing mailers

    Proportion of Geisinger patients who schedule an appointment, comparing relative efficacy of the interventions. Note: this analysis will inform internal operations but will not be reported in publication.

    Time frame: 14 days

  2. Patients - Calls to scheduling line

    Proportion of Geisinger patients who call the appointment scheduling line.

    Time frame: 30 days

07

Study locations

1 site
  • Geisinger
    Danville, Pennsylvania 17822, United States
08

References and documents

Study documents

  • Statistical analysis plan · Aug 2, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency.

Supporting information: Sap, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05000619
Lead sponsor
Geisinger Clinic
Responsible party
Amir Goren (Program Director, Behavioral Insights Team, Geisinger Clinic) — Principal investigator
First posted
Aug 11, 2021
Start date
Jul 12, 2021
Primary completion
Aug 26, 2021
Completion
Aug 26, 2022
Last update
Dec 1, 2022

Study contacts

Amir Goren, PhD
principal investigator · Geisinger Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion